Opens in a new tab
Tuesday, 17 November 2026
EVIDENCE. INTERPRETED.
Disease & Drugs

Research

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Research

139 stories · every one Fact-Checked
CLISResearchClosed-Loop Insulin Delivery Systems: The New StandardClosed-loop insulin delivery systems are advancing Type 1 diabetes care through automated insulin dosing, improved time-in-range, and reduced hypoglycemia. Written…25 Jan 2026 · 7 min read
Fact-Checked
arek-adeoye-ljoCgjs63SM-unsplashLifestyleSmall Steps, Longer Lives: Lancet Study Links Minutes of Movement to Lower Death RiskPhoto by Arek Adeoye on Unsplash A new Lancet meta-analysis shows that adding just a few minutes of daily physical…19 Jan 2026 · 4 min read
Fact-Checked
Neurocrine (2)ResearchINGREZZA Shows Nearly Double VMAT2 Target Occupancy Compared to AUSTEDO XR in First Head-to-Head Study, Neurocrine ReportsNeurocrine Biosciences reports first head-to-head PET imaging data showing INGREZZA achieved nearly double VMAT2 target occupancy compared with AUSTEDO XR…16 Jan 2026 · 3 min read
Fact-Checked
Libre Assist_Predicted-Impact-Tips-Chicken-DinnerResearchAbbott Launches Libre Assist in Libre App to Improve In-the-Moment Food Decisions for People with DiabetesAbott…6 Jan 2026 · 4 min read
Fact-Checked
PolyrizonResearchPolyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral BlockerPolyrizon Ltd. has submitted a Pre-Request for Designation (Pre-RFD) to the U.S. Food and Drug Administration for PL-16, its investigational Viral Blocker nasal spray.4 Jan 2026 · 2 min read
Fact-Checked
NimesulideDrugs Safety AlertNimesulide’s Rise and Reckoning in India: Ending with a Nationwide Ban on High-Dose UseA detailed look at nimesulide in India, from its widespread use to mounting safety concerns, regulatory scrutiny, and the final…3 Jan 2026 · 6 min read
Fact-Checked
CORCEPT CRLResearchFDA Issues Third CRL for Outlook Therapeutics’ ONS-5010/LYTENAVA in Wet AMD – What It MeansFDA issued a Complete Response Letter for Outlook Therapeutics’ ONS-5010/LYTENAVA for wet AMD, requesting more confirmatory data. Learn what this…1 Jan 2026 · 3 min read
Fact-Checked
Semaglutide-NAIONResearchSemaglutide and Eye Health: A Look at NAION RiskSemaglutide has been linked to rare cases of non-arteritic anterior ischemic optic neuropathy (NAION). Learn what current studies, regulators, and…1 Jan 2026 · 6 min read
Fact-Checked
CORCEPT CRLResearchCorcept Therapeutics Receives FDA Complete Response Letter for Relacorilant in Hypertension Secondary to HypercortisolismCorcept Therapeutics has received an FDA Complete Response Letter for relacorilant in hypertension secondary to hypercortisolism. Learn what the CRL…31 Dec 2025 · 4 min read
Fact-Checked
GenmabResearchGenmab Halts Clinical Development of Acasunlimab After Portfolio Review, Shifts Focus to Late-Stage Oncology PipelineGenmab A/S has announced that it will discontinue clinical development of its investigational cancer therapy acasunlimab after a strategic portfolio review.30 Dec 2025 · 3 min read
Fact-Checked
PFASDrugs Safety AlertFDA Says PFAS Safety in Cosmetics Remains Uncertain Due to Data GapsFDA’s MoCRA report finds insufficient data to determine the safety of PFAS, often called forever chemicals, in cosmetics, highlighting major…30 Dec 2025 · 5 min read
Fact-Checked
FESILTYNew Drug ApprovalGrifols’ FESILTY (Fibrinogen): Evidence, Safety, and Clinical Use ExplainedThe U.S. FDA has approved FESILTY (fibrinogen, human-chmt) for the treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency (CFD), including hypo- or afibrinogenemia.…27 Dec 2025 · 4 min read
Fact-Checked
Page 5 of 12